Literature DB >> 27021013

Positive Role for a Negative Calcineurin Regulator in Cardiac Hypertrophy.

Chen Gao1, Yibin Wang2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27021013      PMCID: PMC4862578          DOI: 10.1161/HYPERTENSIONAHA.116.07140

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  10 in total

1.  Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling.

Authors:  Malik Bisserier; Magali Berthouze-Duquesnes; Magali Breckler; Florence Tortosa; Loubina Fazal; Annélie de Régibus; Anne-Coline Laurent; Audrey Varin; Alexandre Lucas; Maxime Branchereau; Pauline Marck; Jean-Nicolas Schickel; Claudine Deloménie; Olivier Cazorla; Pauline Soulas-Sprauel; Bertrand Crozatier; Eric Morel; Christophe Heymes; Frank Lezoualc'h
Journal:  Circulation       Date:  2014-11-04       Impact factor: 29.690

2.  Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin.

Authors:  Fan Pan; Luo Sun; David B Kardian; Katharine A Whartenby; Drew M Pardoll; Jun O Liu
Journal:  Nature       Date:  2007-01-17       Impact factor: 49.962

3.  A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.

Authors:  J D Molkentin; J R Lu; C L Antos; B Markham; J Richardson; J Robbins; S R Grant; E N Olson
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

Review 4.  Central modulation of cyclosporine-induced hypertension.

Authors:  Hanan M El-Gowelli; Mahmoud M El-Mas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-11-29       Impact factor: 3.000

5.  A conserved family of calcineurin regulators.

Authors:  T J Kingsbury; K W Cunningham
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

6.  Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A.

Authors:  Yasuhiro Maejima; Soichiro Usui; Peiyong Zhai; Masayuki Takamura; Shuichi Kaneko; Daniela Zablocki; Mitsuhiro Yokota; Mitsuaki Isobe; Junichi Sadoshima
Journal:  Circ Heart Fail       Date:  2014-02-13       Impact factor: 8.790

7.  Plasma membrane Ca2+-ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents.

Authors:  Xu Wu; Baojun Chang; N Scott Blair; Michelle Sargent; Allen J York; Jeffrey Robbins; Gary E Shull; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2009-03-16       Impact factor: 14.808

Review 8.  Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes.

Authors:  Beate Fiedler; Kai C Wollert
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

9.  Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation.

Authors:  N A Clipstone; G R Crabtree
Journal:  Nature       Date:  1992-06-25       Impact factor: 49.962

10.  Cardiac-Specific EPI64C Blunts Pressure Overload-Induced Cardiac Hypertrophy.

Authors:  Xuehai Zhu; Jing Fang; Jun Gong; Jun-Hong Guo; Guang-Nian Zhao; Yan-Xiao Ji; Hong-Yun Liu; Xiang Wei; Hongliang Li
Journal:  Hypertension       Date:  2016-03-28       Impact factor: 10.190

  10 in total
  3 in total

Review 1.  Calcineurin in development and disease.

Authors:  Lei Chen; Min Song; Chunyan Yao
Journal:  Genes Dis       Date:  2021-03-15

2.  Sanggenon C protects against pressure overload‑induced cardiac hypertrophy via the calcineurin/NFAT2 pathway.

Authors:  Lili Xiao; Yulei Gu; Lu Gao; Jiahong Shangguan; Yang Chen; Yanzhou Zhang; Ling Li
Journal:  Mol Med Rep       Date:  2017-08-18       Impact factor: 2.952

Review 3.  miR-133: A Suppressor of Cardiac Remodeling?

Authors:  Ning Li; Heng Zhou; Qizhu Tang
Journal:  Front Pharmacol       Date:  2018-08-17       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.